The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016
Open accessAbstract
Globally, group B Streptococcus (GBS) remains a leading cause of sepsis and meningitis in infants in the first 90days of life. Intrapartum antibiotic prophylaxis (IAP) for women at increased risk of transmitting GBS to their newborns has been effective in reducing part, but not all, of the GBS disease burden in many high income countries (HICs). In low- and middle-income countries (LMICs), IAP use is low. Immunization of pregnant women with a GBS vaccine represents an alternative strategy to protecting newborns and young infants, through transplacental antibody transfer and potentially by reducing new vaginal colonization. This vaccination strategy was first suggested in the 1970s and several potential GBS vaccines have completed phase I/II clinical trials. During the 2015 WHO Product Development for Vaccines Advisory Committee meeting, GBS was identified as a high priority for the development of a vaccine for maternal immunization because of the major public health burden posed by GBS in LMICs, and the high technical feasibility for successful development. Following this meeting, the first WHO technical consultation on GBS vaccines was held on the 27th and 28th of April 2016, to consider development pathways for such vaccines, focused on their potential role in reducing newborn and young infant deaths and possibly stillbirths in LMICs. Discussion topics included: (1) pathophysiology of disease; (2) current gaps in the knowledge of global disease burden and serotype distribution; (3) vaccine candidates under development; (4) design considerations for phase III trials; and (5) pathways to licensure, policy recommendations and use. Efforts to address gaps identified in each of these areas are needed to establish the public health need for, the development and deployment of, efficacious GBS vaccines. In particular, more work is required to understand the global disease burden of GBS-associated stillbirths, and to develop quality-assured standardized antibody assays to identify correlates of protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Group B Streptococcus vaccines are currently in trials of maternal vaccination, with the aim of inducing maternal antibodies that cross the placenta and protect the newborn passively118.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005
Phares, C. R. (2008) · JAMA · doi:10.1001/jama.299.17.2056 · Cited by 883
Baker, C. J., & Kasper, D. L. (1976) · New England Journal of Medicine · doi:10.1056/nejm197604012941404 · Cited by 676
Self-citationEdmond, K. M., Kortsalioudaki, C., Scott, S., Schrag, S. J., Zaidi, A. K., Cousens, S., & Heath, P. T. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61651-6 · Cited by 600
Self-citationEpidemiology of Group B Streptococcal Disease in the United States: Shifting Paradigms
Schuchat, A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.3.497 · Cited by 600
The infectious origins of stillbirth
Goldenberg, R. L., & Thompson, C. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/s0002-9378(03)00470-8 · Cited by 344
Schrag, S. J., & Verani, J. R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.056 · Cited by 314
Self-citationRevisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease
Jordan, H. T., Farley, M. M., Craig, A. S., Mohle‐Boetani, J. C., Harrison, L. H., Petit, S., Lynfield, R., Thomas, A. R., Zansky, S. M., Gershman, K. A., et al. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318180b3b9 · Cited by 193
Self-citationOkike, I. O., Johnson, A. P., Henderson, K. L., Blackburn, R. M., Müller‐Pebody, B., Ladhani, S. N., Anthony, M., Ninis, N., Heath, P. T., for the neoMen Study Group, et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu514 · Cited by 181
Madhi, S. A., Cutland, C., Jose, L., Koen, A. L., Govender, N., Wittke, F., Olugbosi, M., Meulen, A. S.-T., Baker, S. A., Dull, P. M., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00152-3 · Cited by 167
Self-citationDeutscher, M., Lewis, M., Zell, E. R., Taylor, T. H., Beneden, C. V., Schrag, S. J., & for the Active Bacterial Core Surveillance Team (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir325 · Cited by 165
Self-citation
Research works printed but not linked: 3
- O'Sullivan, 2016, Group B Streptococcal (GBS) disease in UK ad Irish infants younger than 90 days of age in 2014–15. Paper presented at the Royal College of Paediatrics and Child Health, 26–28 April, 2016, Liverpool, UK Abstract published, Arch Dis Child, 101, 1
- Akanmori, 2015, The African Vaccine Regulatory Forum (AVAREF): a platform for collaboration in a public health emergency, WHO Drug Inform, 29, 127
- World Health Organization, 2016, Global Advisory Committee on vaccine safety 15–16 June 2016, Wkly Epidemiol Rec, 28, 341
Cited by
Sorted by citations
Items 101–105 of 105
Limaye, R. J., Schue, J. L., Fesshaye, B., Singh, P., Miller, E. A., Souza, R. T., Jessani, S., Temmerman, M., Badzi, C. D., Sauer, M. A., et al. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004562 · Cited by 1
Pregnancy and Perinatal Infections
Akdöner, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-15221-3_14
Progress in the synthesis of group B Streptococcus capsular oligosaccharides
Geng, X., Meng, W., Li, F., Teng, X., & Gao, J. (2026) · Organic Chemistry Frontiers · doi:10.1039/d6qo01233g
Maternal Immunization: Optimizing Passive Immunity in the Newborn
Michie, C. A. (2026) · Newborn · doi:10.5005/jp-journals-11002-0173 · Cited by 1
Metadata
- Authors
- Kobayashi, M., Schrag, S. J., Alderson, M. R., Madhi, S. A., Baker, C. J., Sobanjo-ter Meulen, A., Kaslow, D. C., Smith, P. G., Moorthy, V. S., & Vekemans, J.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Program for Appropriate Technology in Health (US)
- University of the Witwatersrand (ZA)
- Baylor College of Medicine (US)
- London School of Hygiene & Tropical Medicine (GB)
- World Health Organization (CH)
- Corresponding author
- Vekemans, Johan
- ORCID
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 37
- Issue
- 50
- Pages
- 7307-7314
- ISSN
- 0264-410X (ISSN-L)
- PMC
- PMC6892266
- OpenAlex
- W2561215256
- Cited by
- 105
- References
- 55
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 12 · 2021: 16 · 2020: 11 · 2019: 11
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Vaccine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Lincoln (University of Nebraska) (submittedVersion, cc-by)
- Funders
- Novartis/GSK
- Bill & Melinda Gates Foundation (OPP1134011)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- Streptococcus agalactiae, maternal immunization, intrapartum antibiotic prophylaxis, neonatal sepsis, neonatal meningitis, stillbirth, transplacental antibody transfer, serotype distribution, disease burden, correlates of protection, antibody assays, vaccine licensure, low- and middle-income countries
- MeSH terms
- Animals, Clinical Trials as Topic, Female, Humans, Pregnancy, Pregnancy Complications, Infectious, Streptococcal Infections, Streptococcus agalactiae, Vaccination, World Health Organization, Infectious Disease Transmission, Vertical, Streptococcal Vaccines, Stillbirth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
